We are pleased to welcome Dr Per Norlén to Xinnate’s board of directors.
Dr Norlén brings over 20 years of experience in clinical drug development and leadership roles at AstraZeneca and several private and publicly listed biotechs, including Alligator Bioscience, Targinta, Evaxion Biotech, and WntResearch. He is currently the CEO of Strike Pharma.
His expertise will be invaluable as we advance our work developing innovative therapies for complex skin conditions and wounds.
